NasdaqGM - Nasdaq Real Time Price USD

Summit Therapeutics Inc. (SMMT)

23.87
+0.78
+(3.38%)
At close: May 16 at 4:00:01 PM EDT
23.85
-0.02
(-0.08%)
Pre-Market: 8:36:39 AM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
0
0
0
705
1,809
Operating Expense
250,433
225,971
609,685
64,326
87,984
Operating Income
-250,433
-225,971
-609,685
-63,621
-86,175
Net Non Operating Interest Income Expense
7,901
4,780
-6,058
-2,888
-242
Other Income Expense
1,804
-97
780
-12,273
-2,174
Pretax Income
-240,728
-221,288
-614,963
-78,782
-88,602
Tax Provision
--
--
--
--
0
Net Income Common Stockholders
-240,755
-221,315
-614,928
-78,782
-88,602
Diluted NI Available to Com Stockholders
-240,755
-221,315
-614,928
-78,782
-88,602
Basic EPS
-0.34
-0.31
-0.99
-0.41
-0.96
Diluted EPS
-0.34
-0.31
-0.99
-0.41
-0.96
Basic Average Shares
727,614.58
718,541.90
619,646.18
193,336.06
92,293.75
Diluted Average Shares
727,614.58
718,541.90
619,646.18
193,336.06
92,293.75
Total Operating Income as Reported
--
-225,998
-609,650
-72,089
-86,186
Total Expenses
250,433
225,971
609,685
64,326
87,984
Net Income from Continuing & Discontinued Operation
-240,755
-221,315
-614,928
-78,782
-88,602
Normalized Income
-242,559
-221,218
-615,960
-66,205
-86,467
Interest Income
--
13,466
10,403
1,513
0
Interest Expense
5,565
8,686
16,461
4,401
242
Net Interest Income
7,901
4,780
-6,058
-2,888
-242
EBIT
-235,163
-212,602
-598,502
-74,381
-88,360
EBITDA
-235,076
-212,513
-598,304
-73,118
-85,905
Reconciled Depreciation
87
89
198
1,263
2,455
Net Income from Continuing Operation Net Minority Interest
-240,755
-221,315
-614,928
-78,782
-88,602
Total Unusual Items Excluding Goodwill
1,804
-97
1,032
-12,577
-2,135
Total Unusual Items
1,804
-97
1,032
-12,577
-2,135
Normalized EBITDA
-236,880
-212,416
-599,336
-60,541
-83,770
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 3/5/2015

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

VKTX Viking Therapeutics, Inc.
28.43
+3.76%
 
IOVA Iovance Biotherapeutics, Inc.
1.6600
-5.68%
 
ACAD ACADIA Pharmaceuticals Inc.
22.26
+26.48%
 
TGTX TG Therapeutics, Inc.
34.36
+2.29%
 
MDGL Madrigal Pharmaceuticals, Inc.
290.96
-0.29%
 
IBRX ImmunityBio, Inc.
2.8400
+6.37%
 
HALO Halozyme Therapeutics, Inc.
52.02
+6.27%
 
VRNA Verona Pharma plc
71.31
+2.56%
 
EXEL Exelixis, Inc.
45.40
-1.86%
 
RXRX Recursion Pharmaceuticals, Inc.
4.5600
+7.29%